Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour

Nature Communications

Volumn 5, Issue , 2014, Pages

  Torrezan, Giovana T ^a   Ferreira, Elisa N ^a   Nakahata, Adriana M ^a   Barros, Bruna D F ^a   Castro, Mayra T M ^a   Correa, Bruna R ^b   Krepischi, Ana C V ^a   Olivieri, Eloisa H R ^a   Cunha, Isabela W ^a   Tabori, Uri ^c   Grundy, Paul E ^d   Costa, Cecilia M L ^a   De Camargo, Beatriz ^e   Galante, Pedro A F ^b   Carraro, Dirce M ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d ALBERTA HEALTH SERVICES   (Canada)

^e INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EXPORTIN 5; MICRORNA; PROTEIN DROSHA; PROTEIN P53; RIBONUCLEASE III; UNCLASSIFIED DRUG; WT1 PROTEIN; DROSHA PROTEIN, HUMAN;

GENE EXPRESSION; MUTATION; RNA; TUMOR;

AMINO ACID SUBSTITUTION; ARTICLE; BIOGENESIS; CARCINOGENESIS; DOWN REGULATION; EXOME; GENE SEQUENCE; HUMAN; HUMAN TISSUE; METAL BINDING; MISSENSE MUTATION; NEPHROBLASTOMA; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROTEIN DOMAIN; SOMATIC MUTATION; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; GENETICS; MOLECULAR GENETICS; MUTATION; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; MUTATION; RIBONUCLEASE III; SEQUENCE HOMOLOGY, AMINO ACID; WILMS TUMOR;

EID: 84902289852     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5039     Document Type: Article

References (45)

1. Honeyman, J. N. et al. Factors associated with relapse and survival in Wilms tumor: a multivariate analysis. J. Pediatr. Surg. 47, 1228-1233 (2012).
2. Reinhard, H. et al. Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies. Oncol. Rep. 20, 463-467 (2008).
3. Coppes, M. J., Haber, D. A. & Grundy, P. E. Genetic events in the development of Wilms' tumor. New Engl. J. Med. 331, 586-590 (1994). (Pubitemid 24265702)
4. Huff, V. Wilms tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat. Rev. Cancer 11, 111-121 (2011).
5. Call, K. M. et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60, 509-520 (1990).
6. Pelletier, J. et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67, 437-447 (1991). (Pubitemid 121001458)
7. Ohlsson, R. et al. IGF2 is parentally imprinted during human embryogenesis and in the Beckwith-Wiedemann syndrome. Nat. Genet. 4, 94-97 (1993). (Pubitemid 23165921)
8. Astuti, D. et al. Germline mutations in DIS3L2 cause the Perlman syndrome of overgrowth and Wilms tumor susceptibility. Nat. Genet. 44, 277-284 (2012).
9. Slade, I. et al. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J. Med. Genet. 48, 273-278 (2011).
10. Reid, S. et al. Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. J. Med. Genet. 42, 147-151 (2005). (Pubitemid 40204369)
11. Varanasi, R. et al. Fine structure analysis of the WT1 gene in sporadic Wilms tumors. Proc. Natl Acad. Sci. USA 91, 3554-3558 (1994). (Pubitemid 24139468)
12. Huff, V. et al. WT1 exon 1 deletion/insertion mutations in Wilms tumor patients, associated with di- and trinucleotide repeats and deletion hotspot consensus sequences. Am. J. Hum. Genet. 56, 84-90 (1995).
13. Koesters, R. et al. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 59, 3880-3882 (1999). (Pubitemid 29393544)
14. Rivera, M. N. et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315, 642-645 (2007). (Pubitemid 46214707)
15. Ruteshouser, E. C., Robinson, S. M. & Huff, V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer. 47, 461-470 (2008). (Pubitemid 351657181)
16. Bardeesy, N. et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat. Genet. 7, 91-97 (1994).
17. Williams, R. D. et al. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin. Cancer Res. 16, 2036-2045 (2010).
18. Wu, M. et al. Biallelic DICER1 mutations occur in Wilms tumours. J. Pathol. 230, 154-164 (2013).
19. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
20. Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419 (2003). (Pubitemid 37187272)
21. Blaszczyk, J. et al. Crystallographic and modeling studies of RNase III suggest a mechanism for double-stranded RNA cleavage. Structure 9, 1225-1236 (2001). (Pubitemid 34025056)
22. Han, J. et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18, 3016-3027 (2004). (Pubitemid 39658171)
23. Sun, W., Li, G. & Nicholson, A. W. Mutational analysis of the nuclease domain of Escherichia coli ribonuclease III. Identification of conserved acidic residues that are important for catalytic function in vitro. Biochemistry 43, 13054-13062 (2004). (Pubitemid 39362775)
24. Takeshita, D. et al. Homodimeric structure and double-stranded RNA cleavage activity of the C-terminal RNase III domain of human dicer. J. Mol. Biol. 374, 106-120 (2007). (Pubitemid 47600229)
25. Torrezan, G. T. et al. A novel SYBR-based duplex qPCR for the detection of gene dosage: detection of an APC large deletion in a familial adenomatous polyposis patient with an unusual phenotype. BMC Med. Genet. 13, 55 (2012).
26. Heravi-Moussavi, A. et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. New Engl. J. Med. 366, 235-242 (2012).
27. Landthaler, A. M., Yalcin, A. & Tuschl, T. The Human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr. Biol. 14, 2162-2167 (2004). (Pubitemid 39623200)
28. Krol, J., Loedige, I. & Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11, 597-610 (2010).
29. Anglesio, M. S. et al. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse-strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J. Pathol. 229, 400-409 (2013).
30. Zhang, H., Kolb, F. a., Jaskiewicz, L., Westhof, E. & Filipowicz, W. Single processing center models for human Dicer and bacterial RNase III. Cell 118, 57-68 (2004). (Pubitemid 38902814)
31. Park, J.-E. et al. Dicer recognizes the 5′ end of RNA for efficient and accurate processing. Nature 475, 201-205 (2011).
32. Li, C.-M. et al. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am. J. Pathol. 160, 2181-2190 (2002). (Pubitemid 34663409)
33. Li, W., Kessler, P. & Williams, B. R. G. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene 24, 457-468 (2005). (Pubitemid 40188593)
34. Maschietto, M. et al. Molecular profiling of isolated histological components of wilms tumor implicates a common role for the Wnt signaling pathway in kidney and tumor development. Oncology 75, 81-91 (2008).
35. Maschietto, M. et al. Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms' tumor onset. Cell Death Dis. 2, e224 (2011).
36. Shi, S. et al. Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis. J. Am. Soc. Nephrol. 19, 2159-2169 (2008).
37. Harvey, S. J. et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. J. Am. Soc. Nephrol. 19, 2150-2158 (2008).
38. O, Z. et al. The inducible deletion of Drosha and microRNAs in mature podocytes results in a collapsing glomerulopathy. Kidney Int. 80, 719-730 (2011).
39. Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R. & Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39, 673-677 (2007). (Pubitemid 46676103)
40. Maschietto, M. et al. Gene expression analysis of blastemal component reveals genes associated with relapse mechanism in Wilms tumour. Eur. J. Cancer 47, 2715-2722 (2011).
41. Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010).
42. Ng, P. C. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812-3814 (2003). (Pubitemid 37442253)
43. Schwarz, J. M., Rödelsperger, C., Schuelke, M. & Seelow, D. Mutation Taster evaluates disease-causing potential of sequence alterations. Nat. Methods 7, 575-576 (2010).
44. Cheadle, C., Vawter, M. P., Freed, W. J. & Becker, K. G. Analysis of microarray data using Z score transformation. J. Mol. Diagn. 5, 73-81 (2003). (Pubitemid 36553428)
45. Triboulet, R., Chang, H., Lapierre, R. J. & Gregory, R. I. Post-transcriptional control of DGCR8 expression by the Microprocessor. RNA 15, 1005-1011 (2009).